Skip to main content

Table 1 Effect size of ratio of MΦ subsets in total SF MΦs with patient reported outcome measures (PROMs)

From: Synovial fluid monocyte/macrophage subsets and their correlation to patient-reported outcomes in osteoarthritic patients: a cohort study

 

CD14+CD16neg-MΦs/total SF MΦs (%)

CD14+CD16+-MΦs/total SF MΦs (%)

CD14lowCD16+-MΦs/total SF MΦs (%)

β (95% CI), adjusted p

β (95% CI), adjusted p

β (95% CI), adjusted p

Overall

 mean KOOS

0.379 (0.179, 0.610), p = 0.006

−0.376 (− 0.642, − 0.132), p = 0.025

−0.761 (− 1.601, − 0.030), p = 0.115

 mean KOOSa

0.380 (0.193, 0.613), p = 0.003

− 0.415 (− 0.682, − 0.178), p = 0.005

−0.545 (− 1.191, 0.048), p = 0.247

 mean WOMAC

0.431 (0.191, 0.710), p = 0.010

−0.459 (− 0.769, − 0.170), p = 0.018

−0.734 (− 1.738, 0.059), p = 0.224

 mean WOMACa

0.380 (0.193, 0.613), p = 0.003

−0.473 (− 0.800, − 0.159), p = 0.023

−0.500 (− 1.335, 0.138), p = 0.463

KOOS

 SYMPTOMS

0.187 (−0.055, 0.453), p = 0.459

−0.177 (− 0.491, 0.114), p = 0.667

−0.372 (− 1.227, 0.479), p = 0.869

 SYMPTOMSa

0.188 (− 0.040, 0.471), p = 0.437

− 0.228 (− 0.539, 0.045), p = 0.389

−0.153 (− 0.904, 0.573), p = 0.988

 PAIN

0.299 (0.066, 0.556), p = 0.069

−0.295 (− 0.594, 0.013), p = 0.215

−0.633 (− 1.526, 0.069), p = 0.271

 PAINa

0.288 (0.023, 0.579), p = 0.156

−0.308 (− 0.642, 0.016), p = 0.244

−0.450 (− 1.195, 0.202), p = 0.554

 ADL

0.477 (0.202, 0.796), p = 0.013

−0.458 (− 0.816, − 0.117), p = 0.054

− 1.094 (− 2.214, − 0.169), p = 0.052

 ADLa

0.482 (0.201, 0.797), p = 0.010

−0.492 (− 0.845, − 0.137), p = 0.038

−0.861 (− 1.788, − 0.127), p = 0.092

 QOL

0.431 (0.170, 0.702), p = 0.010

− 0.497 (− 0.792, − 0.215), p = 0.008

−0.463 (− 1.508, 0.432), p = 0.813

 QOLa

0.453 (0.253, 0.667), p = 0.002

−0.571 (− 0.826, − 0.357), q < 0.001

−0.231 (− 0.954, 0.459), p = 0.932

 SPORTS

0.502 (0.223, 0.869), p = 0.009

−0.454 (− 0.901, − 0.101), p = 0.104

−1.244 (− 2.164, − 0.512), p = 0.005

 SPORTSa

0.491 (0.213, 0.865), p = 0.014

−0.475 (− 0.925, − 0.122), p = 0.071

−1.033 (− 1.839, − 0.347), p = 0.031

WOMAC

 PAIN

0.322 (0.084, 0.608), p = 0.059

−0.327 (− 0.659, − 0.035), p = 0.137

−0.655 (− 1.616, 0.116), p = 0.330

 PAINa

0.312 (0.040, 0.616), p = 0.122

−0.347 (− 0.711, − 0.016), p = 0.167

−0.378 (− 1.203, 0.318), p = 0.753

 FUNCTION

0.477 (0.202, 0.795), p = 0.013

−0.458 (− 0.816, − 0.117), p = 0.054

−1.093 (− 2.213, − 0.168), p = 0.053

 FUNCTIONa

0.482 (0.201, 0.797), p = 0.010

−0.492 (− 0.845, − 0.137), p = 0.037

−0.860 (− 1.788, − 0.127), p = 0.092

 STIFFNESS

0.479 (0.194, 0.788), p = 0.010

− 0.592 (− 0.922, − 0.274), p = 0.007

−0.454 (− 1.517, 0.413), p = 0.815

 STIFFNESSa

0.453 (0.159, 0.777), p = 0.019

−0.580 (− 0.924, − 0.247), p = 0.010

−0.262 (− 1.217, 0.450), p = 0.951

  1. All correlations adjusted for sex, body mass index and age; N = 83. Values in boldface show results with significant effect estimates (β)
  2. monocytes/macrophages, SF synovial fluid, SFLs synovial fluid leukocytes, KOOS Knee Injury and Osteoarthritis Injury Score, WOMAC Western Ontario and McMaster Universities Osteoarthritis Index, ADL activities of daily living, QOL quality of life
  3. aAdditionally adjusted for osteoarthritis state (i.e. early, Kellgren–Lawrence (KL) grade I/II, n = 24 or late, KL grade III/IV, n = 52); N = 76